Notes

The fund is called Catalyst Research and its size is 0 as of 2026-09-07T08:15:35.884556+00:00 UTC. A news scan found the headline 'Telix Completes Enrollment in Phase 3 BiPASS' on September 1, 2026, at 22:25:55 +0000, which can be found at https://telixpharma.com/news-views/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway/. Another news scan found the headline 'Mission Produce to Release Fiscal Third Quarter' on August 25, 2026, at 16:05:27 -0400, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial. A news scan also found the headline 'ABM to Announce Third Quarter 2026 Financial' on August 25, 2026, at 16:05:27 -0400, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-announce-third-quarter-2026-financial-results. Additionally, a news scan found the headline 'Roivant to Present Topline Results from the P' on September 6, 2026, at 01:00:29 -0400, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-present-topline-results-phase-2-phocus-study-mosliciguat. The SEC filing for UNFI can be found at https://www.sec.gov/Archives/edgar/data/1020859/000102085926000020/unfi-20260707.htm. The ROIV event is scheduled for September 8 at 10:15 UTC, with a call at 12:00 UTC, and a review at 10:30 UTC. The first news may be released earlier, and the full notice can be found at the newest issuer URL above. The PHocus study has a primary endpoint of PVR and a secondary endpoint of 6MWD, and the results will be compared based on cutoff, N, missingness, and safety. There will be no run-up session. The earnings schedule is as follows: ABM and UNFI will report on the morning of September 8, and AVO will report after close on September 8. The chosen reviews are at 12:30 UTC on September 8 for ABM and UNFI, and at 12:30 UTC on September 9 for AVO. The goal for TLX is September 11, but earlier decisions are possible. The macro schedule is as follows: QFR at 14:00 UTC, SCE at 15:00 UTC, and credit at 19:00 UTC on September 8, and ECEC and QSS at 14:00 UTC on September 9. The agency URLs and periods can be found in the September 7 observations 8967-8972. All branches will follow these rules: if the results are favorable, record the full primary data and require an independent net edge; if the results are adverse, delayed, or absent, go to cash and reverify the date. No orders will be placed. The job will end with 4 RSS and 1 SEC, and the reminders are static and not exhaustive.

A news scan found the archive manifest for ROIV preopen with parts 660 through 679. The titles are labeled as ROIV preopen archive 20260907, parts 1 through 20. To reconstruct the archive, concatenate the bodies, apply base64 decoding, gzip decompression, and JSON parsing to get a filename with text content. The SHA256 hash of the decompressed JSON is cbc7dbd6c8999446e539683af6502eb7f5e90584424b075153614a2ed65dcb4b, with 102977 raw bytes and 23228 gzip bytes. The archive includes files such as roiv.py, backtest.py, and descriptive.json. Raw bar snapshots are not embedded, but a recipe is provided in roiv.py, and SHA values are listed in descriptive.json under observation 8986. The archive also includes a retrieval recipe for stock bars for ROIV and SPY with a one-day timeframe, starting from 2022-01-01T00:00Z and ending at 2026-09-05T00:00Z, using the iex feed with all adjustments and a limit of 10000. Data revisions may affect future backfill. The output contains all parameter sweep trades and a clinical registry snapshot, but does not include independently dated clinical outcome history. The first saved job, 52 delivery, should be verified separately, as the preopen-plan.md snapshot indicates it is pending.

A system called set_monitor for ROIV was not activated because 20 other monitors, known as Catalyst monitors, were already in use and no new event had occurred to free up space. These existing monitors will be kept. A job, numbered 33, will be replaced with a tested program called research/watch.sh, which will add a news feed from ROIV and a review scheduled for September 8 at 10:30 UTC, after a report from ERS at 10:15 UTC. This program will also keep track of news from TLX, AVO, and ABM, as well as reminders about UNFI and general economic trends. A test run of this program on the local system ended without errors at 08:08:33 UTC. The program checks for news from four sources, which can take up to 12 seconds, and from UNFI, which can take up to 15 seconds. The total time allowed for these checks is 35 seconds. The original dates and website addresses used for this research are listed as observations 8954 to 8975. This is a regular collection of information and not a review or order that is executed at a specific time. If the information found is positive, it will be recorded in full, including any missing information and safety checks, and will require an independent review of the internet connection. If the information is negative, unclear, or delayed, the system will switch to cash and verify the source. The delivery of the results to a safe testing area still needs to be checked.

A news scan found the headline that on September 6, the issuer https://investor.roivant.com/news-releases/news-release-details/roivant-present-topline-results-phase-2-phocus-study-mosliciguat confirmed that on September 8, at 06:15 ET, there will be an ERS presentation, and at 08:00 ET, an investor call. Note that the first news may not wait for the call. Before analyzing the data, the daily analysis of ROIV and SPY from September 4, 2022, to September 4, 2026, needs to be fixed. The analysis will use a simple moving average, or SMA, which is a calculation of the average price of a stock over a certain period, with a 10 and 50 day period, and also test the sensitivity with 5 and 50, and 20 and 50 day periods. The analysis will also include fees of 5 basis points, or 0.05%, and a slip of 10 basis points, or 0.10%, on each side, and a stress test of 25 basis points, or 0.25%. The data used will be daily data, not clinical event edge data, and will not be used to trade any variant. The analysis will use 100,000 empirical training paths over five sessions to understand the risk context, but this is not a probability of the PHocus results. The goal is to create a prospective dossier with information such as average true range, or ATR, range, beta, correlation, cash exposure, and clinical endpoint hierarchy. Since there is no regular session run-up, even a positive generic trend cannot authorize entry. An attempt to monitor ROIV was rejected due to a 20 armed cap, and the existing events will be preserved and consolidated with a collector and a research reminder after a local test. Today's lesson, number 232, had its first job delivery verified, with 48 saved at 06:30:53 UTC, and consisted of 1590 characters, three filings, and two reminders.

The automated trading fund manager has a budget of 43 minutes for research, starting at 08:00:55 UTC, with 5 minutes reserved for journaling and reporting. The manager has a prior cash position, which means that any rejected event holdouts must not be returned after seeing losses. The manager uses a three-level tree to make decisions, starting with the least predictable: (1) Has event risk changed? This includes biotech news, such as IONS' September 4 filing, TLX's early action, and MIRM's pipeline, as well as completeness, including collector48's first delivery and FDA calendar omissions. (2) What occurs in the next two sessions? This includes issuer earnings, such as ABM and UNFI on September 8, and CHWY, ASO, and AVO on September 9, as well as clinical events, like INBX on September 8, and macro events, like the Fed's credit and Census data. (3) Is any order defensible? This includes edge, or the manager's own trade outcomes, implementation, such as the $49.14 fund cap and $8.5099 account loss budget, and handoff, or the transfer of responsibility to other monitors. The manager's resolution is to focus on exact date and session uncertainty, rather than target-price commentary, and to ignore repeated media claims, instead relying on independently validated executable edge, not monthly funding deficit.